Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short-term Investments: 2020-2024

Historic Short-term Investments for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2024 value amounting to $10.2 million.

  • Xeris Biopharma Holdings' Short-term Investments fell 48.72% to $10.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.2 million, marking a year-over-year decrease of 48.72%. This contributed to the annual value of $5.0 million for FY2023, which is N/A change from last year.
  • As of Q3 2024, Xeris Biopharma Holdings' Short-term Investments stood at $10.2 million, which was down 49.06% from $20.0 million recorded in Q2 2024.
  • Xeris Biopharma Holdings' 5-year Short-term Investments high stood at $96.2 million for Q4 2020, and its period low was $5.0 million during Q4 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Short-term Investments averaged around $21.2 million, with its median value being $19.9 million (2023).
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Short-term Investments slumped by 72.16% in 2022, and later surged by 112.78% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Short-term Investments stood at $96.2 million in 2020, then crashed by 63.45% to $35.2 million in 2021, then plummeted by 72.16% to $9.3 million in 2022, then skyrocketed by 112.70% to $5.0 million in 2023, then tumbled by 48.72% to $10.2 million in 2024.
  • Its Short-term Investments was $10.2 million in Q3 2024, compared to $20.0 million in Q2 2024 and $24.7 million in Q1 2024.